STIFEL FINANCIAL CORP - REATA PHARMACEUTICALS INC ownership

REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 161 filers reported holding REATA PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.58 and the average weighting 0.2%.

Quarter-by-quarter ownership
STIFEL FINANCIAL CORP ownership history of REATA PHARMACEUTICALS INC
ValueSharesWeighting
Q2 2023$1,527,674
+13.1%
14,983
+0.8%
0.00%0.0%
Q1 2023$1,350,975
+230.6%
14,859
+38.1%
0.00%
+100.0%
Q4 2022$408,629
+59.6%
10,756
+5.8%
0.00%
Q3 2022$256,000
-19.2%
10,169
-2.6%
0.00%
Q2 2022$317,000
-8.6%
10,437
-1.4%
0.00%
Q1 2022$347,000
+37.2%
10,584
+10.4%
0.00%
Q4 2021$253,000
-94.3%
9,590
-78.3%
0.00%
-100.0%
Q3 2021$4,455,000
-29.7%
44,284
-1.1%
0.01%
-22.2%
Q2 2021$6,334,000
+51.0%
44,759
+6.4%
0.01%
+28.6%
Q1 2021$4,195,000
-12.8%
42,075
+8.1%
0.01%
-22.2%
Q4 2020$4,812,000
+61.9%
38,923
+27.5%
0.01%
+50.0%
Q3 2020$2,973,000
-47.0%
30,521
-15.1%
0.01%
-53.8%
Q2 2020$5,612,000
+9.3%
35,970
+1.0%
0.01%
-7.1%
Q1 2020$5,134,000
-17.3%
35,624
+16.9%
0.01%
+7.7%
Q4 2019$6,210,000
+149.5%
30,466
-2.0%
0.01%
+116.7%
Q3 2019$2,489,000
-13.5%
31,072
+1.7%
0.01%
-14.3%
Q2 2019$2,879,000
+4.8%
30,553
-4.5%
0.01%
-12.5%
Q1 2019$2,747,000
+70.7%
31,985
+11.7%
0.01%
+60.0%
Q4 2018$1,609,000
-36.9%
28,629
-8.5%
0.01%
-28.6%
Q3 2018$2,550,000
+155.8%
31,278
+8.7%
0.01%
+133.3%
Q2 2018$997,000
+73.4%
28,786
+2.2%
0.00%
+50.0%
Q1 2018$575,000
+151.1%
28,170
+247.7%
0.00%
+100.0%
Q4 2017$229,0008,1010.00%
Other shareholders
REATA PHARMACEUTICALS INC shareholders Q3 2022
NameSharesValueWeighting ↓
CPMG Inc 3,063,567$298,453,00049.63%
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE 150,000$14,613,00019.62%
Corriente Advisors, LLC 300,000$29,226,00014.82%
Prosight Management, LP 114,554$11,160,0005.31%
MADDEN SECURITIES Corp 43,927$4,279,0003.18%
LBJ Family Wealth Advisors, Ltd. 30,368$2,958,0002.24%
Biondo Investment Advisors, LLC 99,652$9,708,0002.10%
Cormorant Asset Management, LP 450,000$43,839,0001.69%
Duquesne Family Office 543,901$52,987,0001.54%
AWH Capital, L.P. 9,500$925,0001.30%
View complete list of REATA PHARMACEUTICALS INC shareholders